Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Epidermal growth factor receptor targeting in cancer
J Mendelsohn, J Baselga - Seminars in oncology, 2006 - Elsevier
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …
Erlotinib in previously treated non–small-cell lung cancer
FA Shepherd, J Rodrigues Pereira… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung …
PW Sperduto, M Wang, HI Robins, MC Schell… - International Journal of …, 2013 - Elsevier
BACKGROUND: A phase 3 Radiation Therapy Oncology Group (RTOG) study subset
analysis demonstrated improved overall survival (OS) with the addition of stereotactic …
analysis demonstrated improved overall survival (OS) with the addition of stereotactic …
Molecular predictors of response to epidermal growth factor receptor antagonists in non–small-cell lung cancer
LV Sequist, DW Bell, TJ Lynch… - Journal of Clinical …, 2007 - ascopubs.org
In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …
most important targets for drug development in oncology. Monoclonal antibodies targeting …
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
MH Cohen, JR Johnson, YF Chen, R Sridhara… - The …, 2005 - academic.oup.com
Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga, CL Arteaga - Journal of Clinical Oncology, 2005 - ascopubs.org
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …
receptor family that is abnormally activated in many epithelial tumors. The aberrant …
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: current knowledge and future directions
W Pao, VA Miller - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …
Epidermal growth factor receptor inhibition strategies in oncology
PM Harari - Endocrine-related cancer, 2004 - erc.bioscientifica.com
Molecular targeting strategies for cancer therapy are distinct from conventional
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …